Annovis Bio, Inc. (ANVS)
NYSE: ANVS · IEX Real-Time Price · USD
12.74
+0.86 (7.24%)
At close: Apr 24, 2024, 4:00 PM
13.10
+0.36 (2.83%)
After-hours: Apr 24, 2024, 7:50 PM EDT
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Maria L. Maccecchini Ph.D. |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | 484-875-3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President and Executive Director |
| Henry Hagopian III, M.B.A. | Chief Financial Officer |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research and Development |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Melissa Gaines | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 424B5 | Filing |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 19, 2024 | 424B5 | Filing |
| Mar 19, 2024 | 424B5 | Filing |
| Mar 15, 2024 | 8-K | Current Report |